Inhibition of cellcell actin-based motility during poxvirus infection by the kinase inhibitor Glivec

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/571173

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Although smallpox, one of the deadliest human pathogens, was eradicated in 1980, the current global climate has resulted in fears that smallpox may be used as a biological weapon. Unfortunately the smallpox vaccine poses a serious health hazard to certain people. We have shown that Glivec, a drug used to treat cancer, has potent anti-viral affects on poxvirus replication. This project will test the effectiveness of Glivec in treating smallpox in an animal model and study how it acts.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2010

Funding Scheme: Early Career Fellowships

Funding Amount: $92,950.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

actin | epithelial morphogenesis | host-pathogen interaction | motility | tyrosine kinase

Related Links